These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 29468713)

  • 21. Nivolumab-Induced Sarcoid-Like Granulomatous Reaction in a Patient With Advanced Melanoma.
    Danlos FX; Pagès C; Baroudjian B; Vercellino L; Battistella M; Mimoun M; Jebali M; Bagot M; Tazi A; Lebbé C
    Chest; 2016 May; 149(5):e133-6. PubMed ID: 27157227
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Erythema nodosum-like panniculitis mimicking disease recurrence: A novel toxicity from immune checkpoint blockade therapy-Report of 2 patients.
    Tetzlaff MT; Jazaeri AA; Torres-Cabala CA; Korivi BR; Landon GA; Nagarajan P; Choksi A; Chen L; Uemura M; Aung PP; Diab A; Sharma P; Davies MA; Amaria R; Prieto VG; Curry JL
    J Cutan Pathol; 2017 Dec; 44(12):1080-1086. PubMed ID: 28901560
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Debilitating erosive lichenoid interface dermatitis from checkpoint inhibitor therapy.
    Davis MJ; Wilken R; Fung MA; Tartar DM
    Dermatol Online J; 2018 Apr; 24(4):. PubMed ID: 29906009
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Dermatologic toxicities of immune checkpoint inhibitors].
    Sibaud V; Boulinguez S; Pagès C; Riffaud L; Lamant L; Chira C; Boyrie S; Vigarios E; Tournier E; Meyer N
    Ann Dermatol Venereol; 2018 May; 145(5):313-330. PubMed ID: 29678394
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Interstitial granulomatous dermatitis and granulomatous arteritis in the setting of PD-1 inhibitor therapy for metastatic melanoma.
    Singh P; Wolfe SP; Alloo A; Gottesman SP
    J Cutan Pathol; 2020 Jan; 47(1):65-69. PubMed ID: 31390071
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Suprabasal acantholytic dermatologic toxicities associated checkpoint inhibitor therapy: A spectrum of immune reactions from paraneoplastic pemphigus-like to Grover-like lesions.
    Chen WS; Tetzlaff MT; Diwan H; Jahan-Tigh R; Diab A; Nelson K; Glitza IC; Kaunitz GJ; Johnson D; Torres-Cabala C; Pacha O; Taube JM; Maloney K; Prieto VG; Curry JL
    J Cutan Pathol; 2018 Oct; 45(10):764-773. PubMed ID: 29943453
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Diverse types of dermatologic toxicities from immune checkpoint blockade therapy.
    Curry JL; Tetzlaff MT; Nagarajan P; Drucker C; Diab A; Hymes SR; Duvic M; Hwu WJ; Wargo JA; Torres-Cabala CA; Rapini RP; Prieto VG
    J Cutan Pathol; 2017 Feb; 44(2):158-176. PubMed ID: 27859479
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Granulomatous/sarcoid-like reactions in the setting of programmed cell death-1 inhibition: a potential mimic of disease recurrence.
    Hiraki T; Hatanaka M; Arimura A; Kawahira H; Kirishima M; Kitazono I; Horinouchi M; Higashi M; Kanekura T; Tanimoto A
    J Cutan Pathol; 2020 Feb; 47(2):154-160. PubMed ID: 31437317
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Development of psoriatic arthritis during nivolumab therapy for metastatic non-small cell lung cancer, clinical outcome analysis and review of the literature.
    Ruiz-Bañobre J; Pérez-Pampín E; García-González J; Gómez-Caamaño A; Barón-Duarte FJ; López-López R; Vázquez-Rivera F
    Lung Cancer; 2017 Jun; 108():217-221. PubMed ID: 28625638
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lupus-like cutaneous reaction following pembrolizumab: An immune-related adverse event associated with anti-PD-1 therapy.
    Shao K; McGettigan S; Elenitsas R; Chu EY
    J Cutan Pathol; 2018 Jan; 45(1):74-77. PubMed ID: 29028121
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Severe bullous skin eruptions on checkpoint inhibitor therapy - in most cases severe bullous lichenoid drug eruptions.
    Reschke R; Mockenhaupt M; Simon JC; Ziemer M
    J Dtsch Dermatol Ges; 2019 Sep; 17(9):942-948. PubMed ID: 31210413
    [No Abstract]   [Full Text] [Related]  

  • 32. Lichenoid and granulomatous dermatitis.
    Magro CM; Crowson AN
    Int J Dermatol; 2000 Feb; 39(2):126-33. PubMed ID: 10692062
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Autoimmune dermatologic toxicities from immune checkpoint blockade with anti-PD-1 antibody therapy: a report on bullous skin eruptions.
    Jour G; Glitza IC; Ellis RM; Torres-Cabala CA; Tetzlaff MT; Li JY; Nagarajan P; Huen A; Aung PP; Ivan D; Drucker CR; Prieto VG; Rapini RP; Patel A; Curry JL
    J Cutan Pathol; 2016 Aug; 43(8):688-96. PubMed ID: 27086658
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cutaneous adverse reactions to anti-PD-1 treatment-A systematic review.
    Simonsen AB; Kaae J; Ellebaek E; Svane IM; Zachariae C
    J Am Acad Dermatol; 2020 Nov; 83(5):1415-1424. PubMed ID: 32320766
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ipilimumab-associated halo-like inflammatory reactions around nevi during therapy for metastatic melanoma.
    Alniemi DT; Fischer A; Greene LA; Pierson JC
    Dermatol Online J; 2018 Jul; 24(7):. PubMed ID: 30261564
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lichenoid dermatitis in three patients with metastatic melanoma treated with anti-PD-1 therapy.
    Joseph RW; Cappel M; Goedjen B; Gordon M; Kirsch B; Gilstrap C; Bagaria S; Jambusaria-Pahlajani A
    Cancer Immunol Res; 2015 Jan; 3(1):18-22. PubMed ID: 25287118
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bilateral Lower Extremity Skin Eruptions in an HIV-Positive Man Receiving Pembrolizumab Monotherapy for Non-Small Cell Lung Cancer.
    Boozalis E; Kwatra SG; Marrone KA
    JAMA Oncol; 2019 Feb; 5(2):261-262. PubMed ID: 30286225
    [No Abstract]   [Full Text] [Related]  

  • 38. Rare and fatal complication of immune checkpoint inhibition: a case report of haemophagocytic lymphohistiocytosis with severe lichenoid dermatitis.
    Choi S; Zhou M; Bahrani E; Martin BA; Ganjoo KN; Zaba LC
    Br J Haematol; 2021 Jun; 193(6):e44-e47. PubMed ID: 33954981
    [No Abstract]   [Full Text] [Related]  

  • 39. Interstitial granulomatous dermatitis with arthritis associated with trastuzumab.
    Martín G; Cañueto J; Santos-Briz A; Alonso G; Unamuno PD; Cruz JJ
    J Eur Acad Dermatol Venereol; 2010 Apr; 24(4):493-4. PubMed ID: 19744176
    [No Abstract]   [Full Text] [Related]  

  • 40. Diffuse hair loss following anti-programmed cell death-1 antibody treatment: a case report with immunohistochemical analysis.
    Komatsu-Fujii T; Otsuka A; Ishida Y; Kaku Y; Yamashita C; Hata A; Kataoka T; Honda T; Kabashima K
    Eur J Dermatol; 2019 Jun; 29(3):326-327. PubMed ID: 31389791
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.